Search Results
Your search for ,Any matches 8114 pages
Showing 2551 - 2600IMbrave150: A New Standard of Care to Treat Hepatocellular Cancers?
In 2007, sorafenib became the first approved systemic therapy for hepatocellular cancers and the first agent to improve overall survival in these patients.1 In a similar multikinase inhibitor strategy, lenvatinib was found to be noninferior to sorafenib in overall survival in the same patient...
Solving the Mystery of Why Colorectal Cancer Is on the Rise in Young Adults
Excluding skin cancer, colorectal cancer is the third most prevalent and lethal cancer among both men and women in the United States.1 Although the risk of developing colorectal cancer increases with age—more than 90% of cases occur in people aged 50 or older2—recent research shows that the...
Molecular Testing in Metastatic Colorectal Cancer: Understanding How, When, and What to Profile
“In line with the emergence of targeted therapies, molecular biomarker testing in metastatic colorectal cancer has evolved over the past decade,” noted Jeanne Tie, MD, MBChB, FRACP, who acknowledged there is confusion about the best ways to use molecular testing in the clinic. Dr. Tie, who is...
KEYNOTE-177: New Analysis Confirms Benefit of Pembrolizumab vs Chemotherapy in Microsatellite Instability–High Advanced Colorectal Cancer
In an updated analysis of the pivotal phase III KEYNOTE-177 trial of pembrolizu-mab for microsatellite instability–high (MSI-H) metastatic colorectal cancer, the benefit of first-line pembrolizumab continued beyond disease progression on the subsequent line of treatment, despite a high crossover to ...
Treating Colorectal Cancer in the Time of COVID-19
The treatment of colorectal cancer has always been something of an art—but never more so than during the COVID-19 pandemic. In the spring of 2020, The ASCO Post asked three experts in this malignancy to share their concerns and their approaches to achieving good patient outcomes while minimizing...
Gastrointestinal Oncology Highlights 2020–2021 Almanac
Cancers of the digestive tract account for 338,090 new cases and 169,280 deaths annually in the United States. Although the overall mortality from these cancers is decreasing, this has been countered by an increase in the incidence of colorectal cancer in young adults. The rising incidence and poor ...
Definitive Ablative Radiation Therapy in Inoperable Locally Advanced Pancreatic Cancer
In a single-institution study reported in JAMA Oncology, Reyngold et al found that definitive hypofractionated ablative radiation therapy following induction chemotherapy was associated with prolonged locoregional control and favorable survival in patients with inoperable locally advanced...
UC Davis Comprehensive Cancer Center Elected as NCCN Member Institution
The National Comprehensive Cancer Network® (NCCN®) announced that its board of directors has voted to elect the University of California (UC) Davis Comprehensive Cancer Center as its newest member institution. UC Davis joins 30 other leading academic cancer centers from across the United States...
I Want to Live Long and I Want to Live Well
I’m a person who doesn’t like uncertainty. I’m also a worrier. So, when my hand kept going to the same spot on the upper part of my left breast near my chest wall, I couldn’t shake the feeling that something wasn’t quite right, which persisted even after a routine mammography failed to find any...
ASTRO Recommendation on COVID-19 Vaccination for Patients Receiving Radiation Therapy
The American Society for Radiation Oncology (ASTRO) has compiled a selection of resources for radiation oncology professionals. The resources were developed by clinical teams and based on the best available information at the time they were posted. Physicians and their patients must make the...
U.S. Population–Based Study of Prevalence of and Risk Associated With Breast Cancer–Predisposition Genes
In a U.S. population–based, case-control study reported in The New England Journal of Medicine, Chunling Hu, MD, PhD, of the Mayo Clinic, Rochester, Minnesota, and colleagues identified the prevalence of and breast cancer risk associated with germline pathogenic variants in established and...
Nivolumab Plus Cabozantinib as First-Line Treatment of Advanced Renal Cell Carcinoma
On January 22, 2021, the U.S. Food and Drug Administration approved the combination of nivolumab and cabozantinib as first-line treatment for patients with advanced renal cell carcinoma.1-3 Supporting Efficacy Data Approval was based on the findings of the phase III, open-label CheckMate 9ER trial...
Adding Apalutamide to Abiraterone/Prednisone Extends Radiographic Progression-Free but Not Overall Survival
The phase III ACIS trial met its primary endpoint at 6 months showing that apalutamide plus abiraterone acetate/prednisone (AAP) extended radiographic progression-free survival vs abiraterone acetate/prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate...
Comparing Radiotherapy Regimens for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
A dose-intensified approach to salvage radiotherapy failed to show superiority to a conventional-dose strategy in patients with biochemically recurrent prostate cancer who had undergone radical prostatectomy, according to the phase III SAKK 09/10 trial presented at the 2021 Genitourinary Cancers...
EV-301 and EV-201 Trials: Enfortumab Vedotin-ejfv Improves Survival in Metastatic Urothelial Cancer
Enfortumab vedotin-ejfv continues to move the needle forward as a validated treatment option for advanced urothelial carcinoma. At the 2021 Genitourinary Cancers Symposium, results from the phase III EV-301 study1 and EV-201 Cohort 22 provided support for the use of this agent in both patients...
Physician-Patient Relationship: Sacred and Sacrosanct
There are many relationships we build at work in our entire lifetime. Some are good, a few are not, and many are somewhere in between. But of all the relationships we are fortunate enough to build, there is no relationship more valuable and gratifying than the one between a physician and a ...
Cardiovascular Risks Associated With Checkpoint Inhibitors and CAR T-Cell Therapy
In just a few years, immunotherapy has risen to become a pillar of cancer care, leading to significantly improved response rates and even cures in previously intractable diseases. Leveraging the immune system to treat cancer, however, also increases the potential for serious off-target effects....
Expert Point of View: Peter Schmid, MD, PhD
According to the invited discussant of UNIRAD,1Peter Schmid, MD, PhD, Lead of the Centre for Experimental Medicine at Barts Cancer Institute, Queen Mary University of London, it remains unclear whether or not everolimus plus hormone therapy is an effective adjuvant regimen for high-risk patients...
No Benefit Found for Everolimus Plus Adjuvant Hormone Therapy in High-Risk Early-Stage Breast Cancer
Everolimus plus hormone therapy improves outcomes in the advanced disease setting but apparently not in the adjuvant setting, according to the results of the UNIRAD trial, presented as a part of the European Society for Medical Oncology (ESMO) Virtual Plenary program.1 “In the UNIRAD study, after...
Expert Point of View: Stephanie Berg, DO
The formal discussant of the CLEAR trial, Stephanie Berg, DO, of Loyola University Medical Center, Chicago, was enthusiastic about these findings. “Traditionally, first-line therapy with vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors led to a median overall survival...
Adjuvant Atezolizumab in Muscle-Invasive Urothelial Carcinoma: IMvigor010
As reported in The Lancet Oncology by Joaquim Bellmunt, MD, PhD, and colleagues, the phase III IMvigor010 trial showed no improvement in disease-free survival with adjuvant atezolizumab vs observation in patients with muscle-invasive urothelial carcinoma. Study Details In the open-label trial, 809...
Olaparib for Previously Treated Patients With Pancreatic Cancer and DDR Genetic Alterations Other Than BRCA Variants
Combined results of two parallel phase II studies reported in JAMA Oncology by Milind Javle, MD, and colleagues indicated that olaparib may have therapeutic value in previously treated patients with platinum-sensitive pancreatic ductal carcinoma with DNA damage repair (DDR) genetic alterations...
Image-Guided Intensity-Modulated Radiotherapy in Patients With Cervical Cancer
Treatment with image-guided intensity-modulated radiotherapy (IG-IMRT) led to reduced late toxicities vs standard three-dimensional (3D) conformal radiotherapy in patients with cervical cancer, according to data presented by Supriya Chopra, MD, and colleagues during the Society of Gynecologic...
Niraparib Plus Bevacizumab Shows Clinical Benefit in Patients With Advanced Ovarian Cancer
The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the Society of Gynecologic Oncology...
Maintenance Olaparib Yields Strong and Sustained Benefit in Ovarian Cancer
In the 5-year follow-up of the pivotal SOLO-1 trial in women with advanced ovarian cancer and a BRCA1/2 mutation, maintenance treatment with olaparib led to a doubling in progression-free survival. William H. Bradley, MD, presented these findings at the Society of Gynecologic Oncology (SGO) 2021...
Frailty May Impact Surgical Outcomes in Patients With Ovarian Cancer
Frailty may be a better predictor of poor surgical outcomes in patients with ovarian cancer than age, according to two studies reported at the Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer. Researchers found that frail patients are less likely to undergo...
PARP Inhibition Shows Efficacy in Ovarian Cancer Regardless of Number of Prior Lines of Chemotherapy, BRCA Mutation Status
Treatment with olaparib is safe and effective for patients with platinum-sensitive relapsed ovarian cancer, regardless of the number of prior lines of chemotherapy received and BRCA mutation status, according to data presented from the phase II LIGHT study by Karen A. Cadoo, MD, at the Society of...
Survey Reveals Workplace Bullying, Gender Discrimination, and Microaggressions Not Uncommon for Women Gynecologic Oncologists
In a survey of 250 female gynecologic oncologists, more than half reported experiencing instances of bullying, gender discrimination, or microaggressions. They also reported that having a female department chair provided no buffer against these forms of gender harassment or discrimination in the...
Noncovalent BTK Inhibitor Pirtobrutinib in Relapsed or Refractory B-Cell Malignancies
In the phase I/II BRUIN trial reported in The Lancet, Anthony R. Mato, MD, and colleagues found that the noncovalent Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib produced durable responses in patients with relapsed or refractory B-cell malignancies, including those previously treated with ...
Use of Chemotherapy and Risk of Alzheimer’s Disease in Colorectal Cancer Survivors
In a retrospective cohort study reported in JCO Oncology Practice, Akushevich et al found that receipt of chemotherapy was associated with a reduced risk of Alzheimer’s disease in colorectal cancer survivors. As stated by the investigators, “Evidence on the nature of the relationship between...
Study Finds Regularly Drinking Sugar-Sweetened Soda May Increase Total and Breast Cancer Mortality
New research published by Koyratty et al in Cancer Epidemiology, Biomarkers & Prevention suggests that patients with breast cancer who drink sugar-sweetened beverages regularly are at increased risk for death from any cause, and from breast cancer in particular. Compared to women who never or...
Older Breast Cancer Survivors May Consider Discontinuing Screening Mammography in the Setting of Limited Life Expectancy
Newly issued mammography screening guidelines for breast cancer survivors aged 75 and older recommend discontinuing routine mammography for those with a life expectancy of less than 5 years and considering discontinuation of routine screening for those with a life expectancy between 5 and 10 years. ...
New Survey Reveals Hesitancy Around COVID-19 Vaccination Among Patients With Hematologic Malignancies and Survivors
A survey of more than 6,500 U.S. patients with blood cancer and survivors revealed that only half are very likely to get a COVID-19 vaccine, while one in three is either unlikely or unsure about it. The nationwide survey was a collaboration between The Leukemia & Lymphoma Society (LLS), Boston...
Why Might Night-Shift Workers Have a Higher Risk of Developing Cancer?
New clues as to why night-shift workers are at an increased risk of developing certain types of cancer were uncovered in a new study published by Koritala et al in the Journal of Pineal Research. The study involved a controlled laboratory experiment that used healthy volunteers who were on...
Effect of Risk-Adapted Therapy on Long-Term Morbidity in Pediatric Patients With Hodgkin Lymphoma
In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Kevin C. Oeffinger, MD, and colleagues found that adoption of risk-adapted therapy in the 1990s was associated with reduced risk of serious chronic health conditions in pediatric Hodgkin lymphoma...
ASCO Guideline Update Offers Four Standards of Care for Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
A recent ASCO guideline update, prompted by data from several phase III randomized controlled trials, summarizes the evidence supporting the best initial treatment options for the management of noncastrate advanced, recurrent, or metastatic prostate cancer. The hope is that the guideline will help...
Belantamab Mafodotin-blmf Plus Pomalidomide and Dexamethasone Elicits Responses in Myeloma
Belantamab mafodotin-blmf combined with pomalidomide and dexamethasone led to a very good partial response or better in approximately three-quarters of patients with multiple myeloma that was double-class or triple-class refractory, according to Suzanne Trudel, MSc, MD, FRCPC, of Princess Margaret...
In Cholangiocarcinoma, Does Chemotherapy Response Vary According to FGFR2 Status?
With inhibitors of fibroblast growth factor receptor 2 (FGFR2) fusion and other genetic alterations now in clinical trials for cholangiocarcinoma, there is interest in better understanding what FGFR2 genetic alterations mean for patients. In particular, little is known about the effects of FGFR2...
Expert Point of View: Rina Hui, MBBS, PhD, and Melina Marmarelis, MD
“It has been a long time coming to see a positive randomized phase III study with a checkpoint inhibitor in relapsed mesothelioma,” said the study’s invited discussant, Rina Hui, MBBS, PhD, Clinical Professor of Medicine, Crown Princess Mary Cancer Centre, Westmead Hospital, University of Sydney,...
Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive Anaplastic Large Cell Lymphoma
On January 14, 2021, crizotinib was approved for treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.1,2 The safety and efficacy of crizotinib have not been established in older...
Tepotinib for Metastatic NSCLC With MET Exon 14–Skipping Alterations
On February 3, 2021, tepotinib was granted accelerated approval for treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14–skipping alterations.1,2 Supporting Efficacy Data Approval was supported by findings from the...
Novel Therapies Under Study in Chronic Myeloid Leukemia
“There is progress whether ye are going forward or backward! The thing is to move.” —Edgar Cayce To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are a few abstracts selected from the meeting...
The Emerging Role of Exercise in Cancer Prevention and Treatment
The holistic benefits derived from exercise in preventing and ameliorating chronic health conditions such as cardiovascular disease and diabetes are well documented. However, less is known about the salutary effects exercise may have across the cancer setting, especially during treatment....
Outcomes With Internal Mammary and Medial Supraclavicular Nodal Irradiation in Stage I to III Breast Cancer
As reported in The Lancet Oncology by Philip M. Poortmans, PhD, Department of Radiation Oncology of the Iridium Netwerk and the Faculty of Medicine and Health Sciences, University of Antwerp, and colleagues, 15-year outcomes of the phase III EORTC 22922/10925 trial show continued reduction in...
New WHO/IAEA Publication Provides Guidance on Radiotherapy Equipment Procurement
New guidance from the World Health Organization (WHO) and the International Atomic Energy Agency (IAEA) on the procurement of radiotherapy equipment could improve access to this life-saving cancer treatment option across the world. The new technical guidance aims to ensure that the selection of...
Cardiovascular Events With Transdermal Estradiol vs LHRH Agonists for Androgen Suppression in Advanced Prostate Cancer
In an analysis from the UK phase II/III PATCH trial reported in The Lancet, Langley et al found no differences in cardiovascular event rates over long-term follow-up with the use of a transdermal estradiol patch vs luteinizing hormone-releasing hormone agonists (LHRHa) for androgen suppression in...
Eprenetapopt Plus Azacitidine in TP53-Mutated MDS and AML
In a Groupe Francophone des Myélodysplasies phase II study reported in the Journal of Clinical Oncology, Cluzeau et al found that the combination of eprenetapopt and azacitidine produced high response rates in previously untreated patients with high-risk TP53-mutated myelodysplastic syndromes (MDS) ...
Idecabtagene Vicleucel for Heavily Pretreated Patients With Relapsed or Refractory Multiple Myeloma
In the pivotal phase II KarMMa study reported in The New England Journal of Medicine, Nikhil C. Munshi, MD, and colleagues found that the B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel produced high response rates in patients with...
Long-Term Follow-up of Adjuvant Imatinib for Localized Gastrointestinal Stromal Tumors
Final analysis of a collaborative intergroup study confirmed the efficacy of adjuvant treatment with imatinib in patients with localized gastrointestinal stromal tumor (GIST) in terms of prolonged relapse-free survival. In the high-risk subgroup, there was a trend toward a better long-term imatinib ...
Mental Health Service Use Among Testicular Cancer Survivors
In a Canadian population-based cohort study reported in the Journal of Clinical Oncology, Raphael et al found that survivors of testicular cancer were more likely to use mental health services in both the short and long term following treatment compared with the general population. Study Details...
